What is Parkinson's Disease Pharmacotherapy

Pharmacotherapy for Parkinson's Syndrome


[1] Yamawaki M, Kusumi M, Kowa H, Nakashima K. Changes in prevalence and incidence of Parkinson's disease in Japan during a quarter of a century. Neuroepidemiology 2009; 32: 263-269, doi: 10.1159 / 000201565

[2] Rijk MC de, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M et al. Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; 54: 21-23

[3] Campenhausen S von, Bornschein B, Wick R, Botzel K, Sampaio C, Poewe W et al. Prevalence and incidence of Parkinson's disease in Europe. Eur Neuropsychopharmacol 2005; 15: 473-4790, doi: 10.1016 / j.euroneuro.2005.04.007

[4] Tan LCS, Venketasubramanian N, Hong CY, Sahadevan S, Chin JJ, Krishnamoorthy ES et al. Prevalence of Parkinson disease in Singapore: Chinese vs Malays vs Indians. Neurology 2004; 62: 1999-2004

[5] Pringsheim T, Jette N, Frolkis A, Steeves TDL. The prevalence of Parkinson's disease: a systematic review and meta-analysis. Mov Disord 2014; 29: 1583-1590, doi: 10.1002 / mds.25945

[6] Reese JP, Winter Y, Balzer-Geldsetzer M, Botzel K, Eggert K, Oertel WH et al. Parkinson's disease: costs of illness in an outpatient cohort. Health Service 2011; 73: 22–29, doi: 10.1055 / s-0030-1247571

[7] Lotharius J, Brundin P. Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat Rev Neurosci 2002; 3: 932-942, doi: 10.1038 / nrn983

[8] Steger M, Tonelli F, Ito G, Davies P, Trost M, Vetter M et al. Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases. Elife 2016, doi: 10.7554 / eLife.12813

[9] Bonifati V. Genetics of Parkinson's disease-state of the art, 2013. Parkinsonism Relat Disord 2014; 20 (Suppl1): 23-28, doi: 10.1016 / S1353-8020 (13) 70009-9

[10] Kalinderi K, Bostantjopoulou S, Fidani L. The genetic background of Parkinson's disease: current progress and future prospects. Acta Neurol Scand 2016; 134: 314-326, doi: 10.1111 / ane.12563

[11] Kilarski LL, Pearson JP, Newsway V, Majounie E, Knipe MDW, Misbahuddin A et al. Systematic review and UK-based study of PARK2 (parkin), PINK1, PARK7 (DJ-1) and LRRK2 in early-onset Parkinson's disease. Mov Disord. 2012; 27: 1522-1529, doi: 10.1002 / mds.25132

[12] Alexander GE. Biology of Parkinson's disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder. Dialogues Clin Neurosci 2004; 6: 259-280

[13] Galvan A, Wichmann T. Pathophysiology of parkinsonism. Clin Neurophysiol. 2008; 119: 1459-1474, doi: 10.1016 / j.clinph.2008.03.017

[14] Ulusoy A, Rusconi R, Perez-Revuelta BI, Musgrove RE, Helwig M, Winzen-Reichert B, Di Monte DA. Caudo-rostral brain spreading of alpha-synuclein through vagal connections. EMBO Mol Med 2013; 5: 1119-1127, doi: 10.1002 / emmm.201302475

[15] Pichler I, Del Greco M F, Gogele M, Lill CM, Bertram L, Do CB et al. Serum iron levels and the risk of Parkinson disease: a Mendelian randomization study. PLoS Med. 2013; 10: e1001462. doi: 10.1371 / journal.pmed.1001462

[16] Galvan A, Devergnas A, Wichmann T. Alterations in neuronal activity in basal ganglia-thalamocortical circuits in the parkinsonian state. Front Neuroanat 2015; 9: 5. doi: 10.3389 / fnana.2015.00005

[17] Wen M-C, Chan LL, Tan LCS, Tan EK. Depression, anxiety, and apathy in Parkinson's disease: insights from neuroimaging studies. Eur J Neurol 2016; 23: 1001-1019, doi: 10.1111 / ene.13002

[18] Clarke CE, Walker MF, Sackley CM. Physiotherapy and Occupational Therapy and Mild to Moderate Parkinson Disease-Reply. JAMA Neurol 2016; 73: 894-895, doi: 10.1001 / jamaneurol.2016.1283.

[19] Tomlinson CL, Herd CP, Clarke CE, Meek C, Patel S, Stowe R et al. Physiotherapy for Parkinson's disease: a comparison of techniques. Cochrane Database Syst Rev 2014: CD002815, doi: 10.1002 / 14651858.CD002815.pub2

[20] Mestre TA, Espay AJ, Marras C, Eckman MH, Pollak P, Lang AE. Subthalamic nucleus-deep brain stimulation for early motor complications in Parkinson's disease-the EARLYSTIM trial: early is not always better. Mov Disord 2014; 29: 1751-1756, doi: 10.1002 / mds.26024

[21] Schuepbach WMM, Rau J, Knudsen K, Volkmann J, Krack P, Timmermann L et al. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med 2013; 368: 610-622, doi: 10.1056 / NEJMoa1205158

[22] Idiopathic Parkinson's Syndrome. S3-guideline of the German Society for Neurology 2016, Working Group of Scientific Medical Societies. Www.dgn.org/images/red_leitlinien/LL_2016/PDFs_Download/030010_LL_langfassung_ips_2016.pdf

[23] Gray R, Ives N, Rick C, Patel S, Gray A, Jenkinson C et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomized trial. Lancet 2014; 384: 1196-1205, doi: 10.1016 / S0140-6736 (14) 60683-8

[24] Eggert K, Ohlwein C, Kassubek J, Wolz M, Kupsch A, Ceballos-Baumann A et al. Influence of the nonergot dopamine agonist piribedil on vigilance in patients With Parkinson Disease and excessive daytime sleepiness (PiViCog-PD): an 11-week randomized comparison trial against pramipexole and ropinirole. Clin Neuropharmacol 2014; 37: 116-122, doi: 10.1097 / WNF.0000000000000041

[25] Goren T, Adar L, Sasson N, Weiss YM. Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline. J Clin Pharmacol 2010; 50: 1420-1428, doi: 10.1177 / 0091270010369674

[26] Badinter F, Amit T, Bar-Am O, Youdim MBH, Weinreb O. Beneficial behavioral, neurochemical and molecular effects of 1- (R) -aminoindan in aged mice. Neuropharmacology 2015; 99: 264-272, doi: 10.1016 / j.neuropharm.2015.05.041

[27] Parkinson Study Group. A controlled trial of rasagiline in early Parkinson's disease: the TEMPO Study. Arch Neurol 2002; 59: 1937-1943

[28] Uitti RJ, Rajput AH, Ahlskog JE, Offord KP, Schroeder DR, Ho MM et al. Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. Neurology 1996; 46: 1551-1556

[29] Pahwa R, Tanner CM, Hauser RA, Sethi K, Isaacson S, Truong D et al. Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study). Mov Disord 2015; 30: 788-795, doi: 10.1002 / mds.26159

[30] Hansen J, Lambert D. Netters Clinical Anatomy. Thieme Verlag 2006

[31] Gerlach M, Reichmann H, Riederer P, Götz W (editors). Parkinson's disease: basics, clinic, therapy. 3rd revised and expanded edition, Vienna, Springer Verlag 2003